Pediatric Phase I Trial and Pharmacokinetic Study of Topotecan Administered as a 24-Hour Continuous Infusion

Cancer Research

Volumn 53, Issue 5, 1993, Pages 1032-1036

  Blaney, Susan M ^a   Balis, Frank M ^b   Cole, Diane E ^b   Craig, Catherine ^b   Reid, Joel M ^c   Ames, Matthew M ^c   Krailo, Mark ^c   Reaman, Gregory ^c   Hammond, Denman ^c   Poplack, David G ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Childrens Study Cancer Group ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOPOTECAN;

ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHILD; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG STRUCTURE; DRUG TOLERANCE; FEMALE; HEMATURIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; NEUTROPENIA; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMAN; INFANT; INFUSIONS, INTRAVENOUS; MALE; NEOPLASMS; SUPPORT, U.S. GOV'T, P.H.S.; TIME FACTORS; TOPOTECAN;

EID: 0027407637     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Liu, L.F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58: 351-375, 1989.
2. Hertzberg, R.P., Holden, K.G., Secht, S.M., Mattern, M.R., Faucette, L.E., and Johnson, R.K. Characterization of structural features of camptothecin essential for topoisomerasc I interaction and for induction of protein-linked DNA breaks in cells. Proc. Am. Assoc. Cancer. Res., 28: 7, 1987.
3. Gottlieb, J.A., Guarino, A.M., Call, J.B., Oliverio, V.T., and Block, J.B. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chem. Rep., 54: 461-470, 1970.
4. Muggia, F.M., Creaven, P.J., Hansen, H.H., Cohen, M.H., and Selawry, S.O. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chem. Rep., 56: 515-521, 1972.
5. Moertel, C.G., Schutt, A.J., Reitemeier, R.J., and Hahn R.G. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chem. Rep., 56: 95-101. 1972.
6. Gottlieb, J.A., and Luce, J.K. Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chem. Rep., 56: 103-105, 1972.
7. Hsiang, Y.H., Hertzberg, R., Hecht, S., and Liu, L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerasc I.J. Biol. Chem., 260: 14873-14878, 1985.
8. Johnson, R.K., McCabe, F.L., Faucette, L.F., Hertzberg, R.P., Kingsbury, W.D., Boehm, J.C., Caranfa, M.J., and Holden, K.G. SK&F 104864, a water soluble analog of camptothecin with broad-spectrum activity in preclinical tumor models. Proc. Am. Assoc. Cancer. Res., 30: 623, 1989.
9. Beijnen, J.H., Smith, B. R., Keijer, W.J., Van Gijn, R., ten Bokkel Huinink, W.W., Vlasveld, L.T., Rodenhuis, S., and Underberg, W.J.M. High-performance liquid chromatographic analysis of the new antitumor drug SK&F 104864-A (NSC 609699) in plasma. J. Pharmacol. Biomed. Anal., 8: 789-794, 1990.
10. Hertzberg, R.P., Caranfa, M.J., Holden, K.G., Jakas, D.R., Gallagher, G., Mattern, M.R., Mong, S.M., Bartus, J.O., Johnson, R.K., and Kingsbury, W.D. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem., 32: 715-720, 1989
11. Kuhn, J., Bums, S., Wall, J., Brown, T., Cagnola, J., Havlin, K., Weiss, G., Koeller, J., Rodriguez, G., Smith, B., Johnson, R., and von Hoff, D. Pharmacokinetics of the topoisomerase I inhibitor, SK&F 104864. Proc. Am. Soc. Clin. Oncol., 9: 70, 1990.
12. Houghton, P.J., Cheshire, P.J., Myers, L., and Houghton, J.A. Evaluation of 9-dimethylaminomethyl-10-hydroxy camptothecin (topotecan) against xenografts derived from adult and childhood tumors. Ann. Oncol., 3 (Suppl. 1); 84, 1992.
13. National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute, 1988.
14. Knott, G.B. MLAB: a mathematical modeling tool. Comput. Programs Biomed., 10: 271-280, 1979.
15. Yamaoka, K., Nakagawa, T., and Uno, T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet Biopharm., 6: 165-175, 1978.
16. Rowinsky, E.K., Grochow, L.B., Hendricks, C.B., Ettinger, D.S., Forastiere, A.A., Hurowitz, L.A., McGuire, W.P., Sartorius, S.E., Lubejko, B.G., Kaufmann, S.H., and Donehower, R.C. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J. Clin. Oncol., 10: 647-656, 1992.
17. Sirott, M.N., Saltz, L., Young, C., Tong, W., Trochanowski, B., Niedzwiecki, D., Toomasi F., and Kelsen, D. Phase I and clinical pharmacologic study of intravenous topotecan. Proc. Am. Soc. Clin. Oncol., 10: 104, 1991.
18. Reid, J.M., Burch, P.A., Benson, L.M., Gilbert, J.A., Richardson, R.L., and Ames, M.M. Phase I and clinical and pharmacologic evaluation of topotecan administered by a 24 hour continuous infusion. Proc. Am. Assoc. Cancer Res., 33: 259, 1992.
19. Verweij, J., Lund, B., Planting, A.S.T., deBoer, M., Koier, I., and Hansen H.H. Clinical studies with topotecan: the EORTC experience. Ann. Oncol., 3 (Suppl. 1): 118, 1992.
20. Recondo, G., Abbruzzese, J., Newman, B., Newman, R., Kuhn, J., von Hoff, D., Garteiz, D., and Raber, M. A phase I trial of topotecan administered by a 24-hour infusion. Proc. Am. Assoc. Cancer Res., 32: 206, 1991.
21. Saltz, L., Sirott, M., Young, C., Niedzwiecki, D., Tong, W., Trochanowski, B., Toomasi, F., and Kelsen, D. Phase I and clinical pharmacologic study of intravenous topotecan alone and with granuloctye-colony stimulating factor (G-CSF). Ann. Oncol., 3 (Suppl. 1): 84, 1992.
22. ten Bokkel Huinink, W.W., Rodenhuis, S., Beijnen, J., Dubbelman, R., and Koier, I. Phase I study of the topoisomerase I inhibitor topotecan (SK & F 104864-A). Ann. Oncol., 3 (Suppl. 1): 84, 1992.
23. Burns, H., Kuhn, J., Wall, J., Eckardt, J., Rodriguez, F., Johnson, R., Weiss, G., Shaffer, D., and von Hoft, D. Early clinical trials of topotecan, a new topoisomerase I inhibitor. Ann. Oncol., 3 (Suppl. 1): 118, 1992.
24. Haas, N.B., Hudes, G.R., Walczak, J., LaCreta, F.P., Brennan, J., Ozols, R.F., and O'Dwyer, P.J. Phase I trial of topotecan on a weekly 24-hour infisional schedule. Ann. Oncol., 3 (Suppl. 1): 84, 1992.